CAPR News and Press, Capricor Therapeutics Inc. From 02/06/19

LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it has resumed per protocol dosing of patients already enrolled in its HOPE-2 clinical trial of CAP-1002, the company’s novel cell the...

CORAL GABLES, FL / ACCESSWIRE / January 24, 2019 / The healthcare stock market has become a hotbed of conversation over the course of the past year or so, with headlines on the industry hitting the media on a consistent basis. Companies in the space have tasked their medical experts and pr...

LOS ANGELES, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Neurology ®, an international peer-reviewed journal, on Wednesday published the results of the HOPE-Duchenne clinical trial that evaluated the safety and efficacy of a single intracoronary dose of Capricor Therapeutics ’ (NASDAQ: ...

LOS ANGELES, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company, today announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the U.S. Food and Drug Administration (FDA) regarding developmen...

UniQure (NASDAQ: QURE ), Tocagen (NASDAQ: TOCA ), Iovance Biotherapeutics (NASDAQ: IOVA ) and Miragen Therapeutics (NASDAQ: MGEN ) all resumed with Buy ratings at B. Riley FBR. More news on: uniQure N.V., Tocagen Inc, Iovance Biotherapeutics, Inc., Healthcare stocks news, , Tech stocks new...

NEW YORK, Dec. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Halozyme Therapeutics, Inc. (NASDAQ:HALO), Capricor Therapeutics, Inc. (N...

Capricor Therapeutics (NASDAQ: CAPR ) announces putting its Duchenne muscular dystrophy trial for lead drug CAP-1002 on hold after a safety review following a severe allergic reaction during infusion. More news on: Capricor Therapeutics, Inc., Healthcare stocks news, Stocks on ...

LOS ANGELES, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report i...

Presentation to Focus on Company’s Therapeutic Pipeline for Duchenne Muscular Dystrophy and other Rare Diseases LOS ANGELES, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc . (NASDAQ: CAPR) will provide a corporate overview of its research and development of cell ...